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A set of neutralizing monoclonal antibodies (mAbs) directed against the GP5 protein of European
type porcine reproductive and respiratory syndrome virus (PRRSV) has been produced previously
(Weiland et al., 1999). This set reacted with a plaque-purified virus (PPV) subpopulation of Dutch
isolate Intervet-10 (I-10), but not with the European prototype PRRSV LV. In order to map the
neutralization epitope in the GP5 protein of the PPV strain, the ORF5 nucleotide sequence of PPV
was determined. When the amino acid sequence derived from this nucleotide sequence was
compared with that of PRRSV LV, four amino acid differences were found. Using site-directed
mutagenesis, we showed that a proline residue at position 24 of theGP5 sequence of the PPV strain
enabled recognition by the neutralizing mAbs. Pepscan analysis demonstrated that the epitope
recognized by the neutralizing mAbs stretched from residues 29 to 35. Surprisingly, the reactivity of
the mAbs in the Pepscan system was independent of the presence of a proline in position 24.
Moreover, residue 24 is located within the predicted signal peptide, implying that either the signal
peptide is not cleaved or is cleaved due to the presence of Pro24 such that the epitope remains
intact. Our results demonstrate the presence of a neutralization epitope in the N-terminal
ectodomain of theGP5 protein of PRRSV and imply a role for the ectodomain of GP5 in the infection
of PRRSV.
INTRODUCTION
Porcine reproductive and respiratory syndrome virus
(PRRSV) is an enveloped RNA virus that belongs to the
Arteriviridae family, along with equine arteritis virus (EAV),
lactate dehydrogenase-elevating virus (LDV) and simian
haemorrhagic fever virus (SHFV) (Meulenberg et al., 1993).
The Arteriviridae family belongs to the order Nidovirales,
together with the Coronaviridae (Cavanagh, 1997). PRRSV
causes respiratory problems and anorexia in pigs and
abortion in sows. The virus has a restricted tropism for
cells of the monocyte/macrophage lineage, presumably by
a cell-specific receptor that has not yet been identified. The
virus has a plus-strand polyadenylated RNA genome of
about 15 kb, which contains at least nine partially over-
lapping open reading frames (ORFs). ORF1a and ORF1ab
constitute about 80% of the genome and encode the
virus replication machinery including the RNA-dependent
RNA polymerase. ORFs 2–7 are located in the 39 terminal
region of the genome and encode structural proteins
(Meulenberg et al., 1995; Meulenberg & Petersen-den
Besten, 1996). ORF7 encodes the nucleocapsid protein N,
ORF6 the non-glycosylated membrane protein M, ORF5
the major envelope glycoprotein GP5 and ORFs 2–4 the
minor envelope glycoproteins GP2, GP3 and GP4, respec-
tively (Meulenberg et al., 1995). Within ORF2, a second
ORF is present that expresses a non-glycosylated pro-
tein (Wu et al., 2001), as has also been reported for EAV
(Snijder et al., 1999).
PRRSV neutralization is correlated with antibodies directed
against the GP5 protein, both in vivo (Gonin et al., 1999;
Kwang et al., 1999; Pirzadeh & Dea, 1998; Yoon et al., 1995)
and in vitro (Pirzadeh & Dea, 1997; Weiland et al., 1999;
Yang et al., 2000; Zhang et al., 1998). Monoclonal antibodies
(mAbs) against the GP4 protein have also been found to be
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neutralizing (Meulenberg et al., 1997), although mAbs
against the GP5 protein appeared to be much more effective
(Weiland et al., 1999).
The GP5 protein is a glycoprotein of approximately
200 amino acids with an apparent molecular mass of
25 kDa. The GP5 protein is the most variable protein
among PRRSV isolates, with only 51–55% amino acid
sequence identity between European and North American
isolates (Indik et al., 2000; Kapur et al., 1996; Mardassi et al.,
1995), with the largest differences observed in the N
terminus. Despite these differences, the hydropathy profiles
of the GP5 proteins of the American and European isolates
are very similar. For North American strains, it has been
demonstrated that the GP5 protein is present as part of a
disulphide-linked heterodimer with the M protein in the
virion (Mardassi et al., 1996). The N terminus of the
GP5 protein contains a predicted signal peptide of about
32 amino acids according to the prediction of von Heijne
(1986), which is followed by a hydrophilic stretch of about
40 amino acids. This domain contains two or three poten-
tial N-linked glycosylation sites at residues 37, 46 and 53
(Indik et al., 2000; Meulenberg et al., 1995; Stadejek et al.,
2002) and a highly conserved core sequence (aa 38–55)
potentially involved in heterodimer formation with the
M protein (Verheije et al., 2002). This N-terminal domain
is presumed to be exposed on the outside of the virion and
is therefore designated the ectodomain. The ectodomain is
followed by a long hydrophobic region of about 60 amino
acids that is presumed to span the membrane either one or
three times. Whether the N-terminal ectodomain con-
stitutes the only exposed part of the protein or whether a
second ectodomain – positioned more C-terminally – exists
is presently unclear (Stadejek et al., 2002). The last 70
C-terminal amino acids are thought to form the endodo-
main (Meulenberg et al., 1995). The GP5 protein, possibly as
a heterodimeric complex with theM protein, is presumed to
play a role in attachment to host-cell receptors (Dea et al.,
2000; Delputte et al., 2002; Snijder &Meulenberg, 1998) and
in virus assembly (Verheije et al., 2003).
PRRSV GP5 is the homologue of the GL protein of EAV
and the VP-3P protein of LDV. For EAV and LDV,
neutralizing epitopes have been mapped to the ectodomain
of their respective GP5 homologues (Balasuriya et al., 1995;
Chirnside et al., 1995; Glaser et al., 1995; Li et al., 1998).
Furthermore, disruption of the disulphide bonds between
the GP5 and the M protein of LDV resulted in loss of viral
infectivity, suggesting that the heterodimers are involved
in receptor binding (Faaberg et al., 1995). In addition, the
ectodomain of the LDV GP5 protein has been reported to
be involved in LDV persistence and pathogenicity (Chen
et al., 2000). On the other hand, the importance of GP5 in
receptor binding, at least for EAV, has been questioned
(Dobbe et al., 2001).
The aim of this study was to determine the location of a
neutralizing epitope in the GP5 protein of European type
PRRSV. Neutralizing mAbs described by Weiland et al.
(1999) were found to be specific for a plaque-purified virus
(PPV) subpopulation of the Dutch PRRSV isolate I-10.
Hence the nucleotide sequence of the ORF5 gene of PPV
was determined and compared with that of PRRSV LV,
which does not react with these mAbs. Site-directed
mutagenesis was used to identify the amino acid residues
essential for recognition of the native protein by the
neutralizing mAbs. Pepscan analysis further defined the
boundaries of the epitope bound by these mAbs.
METHODS
Cells and viruses. Baby hamster kidney (BHK-21) cells were grown
in BHK-21 medium (Gibco BRL) with 5% foetal bovine serum (FBS),
10% tryptose phosphate broth (Gibco BRL), 20 mM HEPES pH 7?4
(Gibco BRL), 200 mM glutamine, 100 U penicillin ml21 and 100 U
streptomycin ml21. Porcine alveolar lung macrophages (PAMs) were
maintained in MCA-RPMI 1640 medium (Gibco BRL) containing
10% FBS, 50 U penicillin ml21 and 50 U streptomycin ml21. The
PPV and EPV (gained by end-point dilution) subpopulations of the
Dutch isolate I-10 and the escape mutant viruses have been described
previously (Weiland et al., 1999).
Monoclonal antibodies and antisera. Three mAbs, P10/a46,
P10/b38 and P4/a2-19, directed against the GP5 protein of the PPV
strain, belong to a set of 15 mAbs that all react against the same
antigenic region on the GP5 protein (Weiland et al., 1999). Mono-
clonal antibody 3AH9 was raised against aa 170–201 of European
type PRRSV (Rodriguez et al., 2001). Peptide serum p703 was raised
against an LV-specific peptide consisting of aa 145–161 of the GP5
protein (Meulenberg et al., 1995).
Construction of mutant ORF5 genes in the pCIneo mamma-
lian expression vector. Plasmid p5a6 containing the ORF5 gene
of the PRRSV PPV strain (Conzelmann et al., 1993) was generously
provided by K. Conzelmann and has been described previously
(Weiland et al., 1999). The ORF5 sequences of pABV437, the PacI
mutant of the genome-length cDNA clone of LV (Meulenberg et al.,
1998), and of plasmid p5a6 were amplified using oligonucleotides
LV275 and LV282, located upstream and downstream of ORF5,
respectively (Table 1). The nucleotide sequence directly upstream of
the start codon of ORF5 was modified to a consensus Kozak
sequence (Kozak, 1987). In addition, the restriction sites XbaI and
NotI were added upstream and downstream of ORF5, respectively.
The PCR fragments were digested with XbaI and NotI and ligated
into the corresponding sites of the pCIneo mammalian expression
vector (Promega). This resulted in plasmids pABV786 and pABV789
containing the ORF5 genes of LV and p5a6, respectively.
Subsequently, three different codons resulting in single amino acid
substitutions were introduced into the LV ORF5 sequence by site-
directed mutagenesis using a fusion PCR (Dekker et al., 2000). The
sequences of the primers that were used are shown in Table 1. Indivi-
dual parts were amplified with the forward or the reverse primer
containing the desired mutation. The two mutated PCR products
were hybridized and amplified with two primers outside the mutation.
The mutated fragments were then digested with XbaI and XhoI and
were reintroduced into the pCIneo vector, resulting in plasmids
pABV803, pABV804 and pABV805, respectively.
The fourth difference between both ORF5 genes, codon 158 (LysRArg),
was introduced in pABV786 by exchange of a XcmI–BlpI fragment
between plasmids pABV786 and pABV789. This resulted in construct
pABV806.
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Construction of a full-length neutralization-sensitive PRRSV
cDNA clone. In order to introduce a proline at aa 24 into
pABV437, a fusion PCR was performed with primers LV46 and
LV286 and with primers LV285 and LV107, respectively. The
mutated fragments were then digested with BstXI and NheI and
ligated into the similarly digested plasmid pABV651, a cDNA clone
encompassing the structural genes of PRRSV LV. From the resulting
clones, the AatII–HpaI fragment was excised and introduced into
pABV437, resulting in full-length construct pABV911. Plasmid con-
structs were amplified and purified using the Qiagen plasmid mini
kit. Recombinant DNA techniques were performed essentially as
described by Sambrook et al. (1989).
Sequence analysis. Fragments generated by PCR were analysed by
nucleotide sequencing. Sequences were determined with the PRISM
Ready Dye Deoxy Terminator cycle sequencing kit and the ABI
PRISM 310 Genetic Analyser (Perkin Elmer).
DNA transfection. BHK-21 cells seeded in 24-well plates were
transfected with plasmids using Lipofectamine (Gibco BRL). Trans-
fection mix was removed after 4 h and replaced with complete
BHK-21 medium, and cells were incubated for another 20 h at
37 ˚C in a CO2 incubator.
Production of infectious virus from full-length genomic
cDNA clones. To obtain infectious virus, the full-length genomic
cDNA clones pABV437 and pABV911 were transcribed in vitro. The
RNAs were then transfected into BHK-21 cells using Lipofectin
(Gibco BRL). The culture supernatant of BHK-21 cells was harvested
24 h after transfection and the supernatant was subsequently used
to inoculate PAMs. After 1 h, the inoculum was removed and fresh
culture medium was added. At 24 h post-infection (p.i.), the super-
natant was harvested and virus titres (expressed as TCID50 ml
21)
were determined on PAMs.
Virus neutralization assay. The sensitivity of viruses vABV437
and vABV911 to neutralization was determined in an immuno-
peroxidase monolayer assay (IPMA) 24 h p.i. PAMs were plated into
96-well microtitre plates and incubated overnight at 37 ˚C. To deter-
mine the neutralization index, twofold serial dilutions of culture
supernatant of mAb P10/a46 were mixed with 100 TCID50 of the
viruses, incubated at 37 ˚C for 1 h and subsequently transferred to
the PAMs. At 24 h p.i., cells were washed with PBS, dried and stored
at 220 ˚C until an IPMA was performed. Monoclonal antibody
122.17 was used to detect the expression of the PRRSV N protein.
Immunoperoxidase monolayer assay. Cells were fixed with cold
96% methanol for 25 min and the GP5 protein expressed by the
various ORF5 constructs was detected with mAb P10/a46, P10/b38
or P4/a2-19 in an IPMA as described by Wensvoort et al. (1986).
Radioimmunoprecipitation. Peptide serum 703 (p703) and mAb
P10/a46 were used to precipitate Tran35S-labelled GP5 proteins from
lysates of BHK-21 cells transfected with the different ORF5 con-
structs. BHK-21 cells transfected with the pCIneo vector were used
as negative control. Cellular proteins were labelled with Tran35S
label in MEM-E without methionine and cysteine (Gibco BRL),
supplemented with 1% L-glutamine, 100 U penicillin ml21 and
100 U streptomycin ml21 for 4 h after starving with the same
medium without label for 30 min. Cells were lysed in PBS contain-
ing 1 g SDS l21, 10 ml Triton X-100 l21 and 5 g sodium desoxycho-
late l21 (PBS-TDS) for 10 min on ice. Cell lysates were mixed with
either an equal volume of hybridoma supernatant or 15 ml of p703
and incubated overnight at 4 ˚C. Subsequently, protein A–Sepharose
(Amersham Pharmacia Biotech) was added and lysates were incu-
bated at 4 C˚ for another 2 h. Immunoprecipitates were then
washed with PBS-TDS, resuspended in loading buffer and samples
analysed by 14% SDS-PAGE. Gels were dried and immunoprecipi-
tated proteins were visualized by autoradiography.
Pepscan analysis. Pepscan analysis was performed using over-
lapping 12-mer peptides as described in Slootstra et al. (1997). Optical
densities (OD) were determined with a ccd-camera. The values are
logarithmic values in a range of 0 to 4000.
Table 1. Primers used for site directed mutagenesis and to clone the ORF5 fragments in the pCIneo mammalian expression
vector
Designation
primer*
Nucleotide
positionD Sequence primerd Purpose
LV46 (+) 13160 GCCGTCGGTACCCCTCAGTACAT Fusion PCR full-length construct
LV107 (2) 14508 CCGAAGCCCGGGTACTAGAGTG Fusion PCR full-length construct
LV275 (+) 13493 GCTCTAGAGCCGCCACCATGAGATGTTCTCACAAATTGGG Incorporation of XbaI+consensus
Kozak sequence
LV282 (2) 14079 ATAGTTTAGCGGCCGCCTAGGCCTCCCATTGCTCAGC Incorporation NotI
LV285 (+) 13549 GGCTTTTTTTGCTGccTACCGGCTTGTCC Cys24RPro24
LV286 (2) 13549 GGACAAGCCGGTAggCAGCAAAAAAAGCC Cys24RPro24
LV287 (+) 13772 CGGTCTCGGCGtTGTATCCACTGCAGG Ala97RVal97
LV288 (2) 13772 CCTGCAGTGGATACAaCGCCGAGACCG Ala97RVal97
LV289 (+) 13789 CCACTGCAGGAcTTGTTGGCGGG Phe103RLeu103
LV290 (2) 13789 CCCGCCAACAAgTCCTGCAGTGG Phe103RLeu103
LV291 (+) 13490 CCGCTCGAGCGGCTGCAGAACCAATGC Incorporation of XhoI
LV292 (+) 13486 GCAGAACCAATGCATTGGCAATATGAGATG Fusion PCR pCIneo constructs
LV293 (2) 14091 CTAGTCTAGACTAGCTAGGCCTCCC Incorporation of XbaI
*Positive-sense primers and negative-sense primers are marked by (+) and (2), respectively.
DThe position of each primer with respect to the nucleotide sequence of PRRSV LV (GenBank accession no. M96262).
dThe restriction sites are indicated by single underlining and the consensus Kozak sequence is indicated by double underlining. The underlined
nucleotides in lower case are mutated compared with the original genome sequence of PRRSV LV.
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RESULTS
A proline residue at position 24 of the GP5
protein is essential for binding of neutralizing
mAbs
A set of neutralizing mAbs directed against the GP5 protein
of PRRSV has been produced previously (Weiland et al.,
1999). This set reacted with a PPV subpopulation of Dutch
isolate I-10, but not with the EPV subpopulation of I-10,
gained by end-point dilution (Weiland et al., 1999), or with
the prototype European PRRSV LV. Plasmid p5a6, con-
taining the ORF5 fragment of the PPV strain, has been
generated previously (Weiland et al., 1999). The nucleotide
sequence of the ORF5 gene in plasmid p5a6 was deter-
mined and compared with that of PRRSV LV, since this
sequence was already available. Nine nucleotide differ-
ences were identified, which resulted in four amino acid
differences in the GP5 protein, i.e. aa 24 (CysRPro), 97
(AlaRVal), 103 (PheRLeu) and 158 (LysRArg) (Fig. 1A).
Subsequently, coding sequences for these four amino
acids were individually introduced into the ORF5 gene of
PRRSV LV in the pCIneo mammalian expression vector
(pABV786), resulting in pABV803, pABV804, pABV805
and pABV806, respectively. In addition, the PPV ORF5
gene was introduced into the pCIneo vector (pABV789).
The generated ORF5 constructs were transfected into
BHK-21 cells. At 24 h post-transfection, the expressed
GP5 proteins were analysed by immunostaining with the
three mAbs P4/a2-19, P10/a46 and P10/b38. Monoclonal
antibody 3AH9, directed against aa 170–201 of European
type PRRSV (Rodriguez et al., 2001), was used as a positive
control. As expected, the GP5 protein expressed from
pABV789, containing the ORF5 gene of the PPV strain, was
recognized by the neutralizing mAbs, whereas the GP5
protein expressed from pABV786, containing the ORF5
gene of the LV strain, was not detected (Fig. 2). The GP5
protein expressed from pABV803, containing the mutation
encoding a proline at position 24 of GP5, was recognized by
the mAbs, whereas the other three mutant GP5 proteins,
expressed from pABV804, -805 and -806, were not detected.
3AH9 recognized all mutant GP5 proteins, confirming that
absence of immunostaining with the neutralizing mAbs
was not due to low expression levels and/or aberrant pro-
cessing of the other mutant GP5 proteins (data not shown).
Thus, aa 24 is essential for recognition by the three neutra-
lizing mAbs, due to either the absence of the cysteine or the
presence of the proline.
Analysis of mutant GP5 proteins by
radioimmunoprecipitation
In order to examine expression and processing of the mutant
GP5 proteins, immunoprecipitations were performed for
radiolabelled GP5 proteins. BHK-21 cells were transfected
with the ORF5 plasmids and labelled with [35S]methionine
and [35S]cysteine. GP5 proteins were immunoprecipitated
(A)
(B)
Fig. 1. (A) Amino acid sequences of GP5 of PRRSV. The four amino acid residues in the GP5 sequence of PPV that differ
from the sequence of the LV strain are indicated below the LV sequence. Putative signal peptide cleavage sites are depicted
by arrows (q). (B) Diagram of the GP5 protein.
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with either mAb P10/a46 or with p703, an anti-peptide
serum directed against aa 145–161 of the LV GP5 protein.
Subsequently, the precipitates were analysed by 14% SDS-
PAGE. P10/a46 precipitated the GP5 protein expressed from
plasmids pABV789 and pABV803 (Fig. 3), whereas p703
precipitated the GP5 proteins expressed from all ORF5
plasmids. This was in agreement with the immunostaining
results. The apparent molecular mass of all precipitated GP5
pABV786 pABV789 pABV803
pABV804 pABV805 pABV806
Fig. 2. Expression of mutant GP5 proteins in BHK-21 cells transfected with plasmids pABV786 (LV), pABV789 (PPV),
pABV803 (Pro24), pABV804 (Val97), pABV805 (Leu103) and pABV806 (Arg158). An immunoperoxidase monolayer assay was
performed with PPV-specific mAb P10/a46 directed against GP5; mAbs P10/b38 and P4/a2-19 gave a similar staining
pattern (data not shown).
Fig. 3. Radioimmunoprecipitation analysis of expressed mutant GP5 proteins with anti-GP5 mAb P10/a46 and peptide serum
p703. Proteins were immunoprecipitated from lysates of BHK-21 cells transfected with pABV786 (LV), pABV789 (PPV),
pABV803 (Pro24), pABV804 (Val97), pABV805 (Leu103) and pABV806 (Arg158). BHK-21 cells transfected with the pCIneo
vector were used as negative control. The immunoprecipitated GP5 proteins were analysed by 14% SDS-PAGE. The GP5
protein is indicated by an arrow. Protein size markers (kDa) are shown on the left.
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proteins seemed to be comparable, indicating that expres-
sion and processing of the GP5 proteins expressed from
pABV789 and -803 were not markedly different from that
of the other GP5 proteins. In addition, p703 precipitated
proteins with an apparent molecular mass of approximately
14 kDa from the lysates of BHK-21 cells transfected with
pABV786, -803 and -806. These proteins were most likely
non-specifically coprecipitated.
Pepscan analysis of the PRRSV GP5 proteins
In order to specify further the boundaries of the neutra-
lization epitope of the GP5 protein, a set of overlapping
12-mer peptides covering the complete GP5 amino acid
sequence of the PPV strain was tested for reactivity with
anti-GP5 mAbs P10/a46, P10/b38 and P4/a2-19 (Slootstra
et al., 1997). All three mAbs reacted specifically with pep-
tides that had the sequence WSFADGN (residues 29–35;
Fig. 4A, B, underlined), while the core sequence consisted
of residues 30–32 (SFA; Fig. 4A, B, bold). In addition, a
small set of twelve 12-mer peptides containing a cysteine
at position 24 was tested for reactivity. Surprisingly, these
peptides gave comparable OD values in the Pepscan analysis,
i.e. the reactivity of the mAbs in the Pepscan system was
independent of the presence of a proline at position 24.
A proline residue at position 24 of GP5 results
in sensitivity to neutralization in vitro
To investigate whether the presence of a proline at position
24 indeed results in sensitivity to neutralization in vitro, a
mutant full-length PRRSV LV cDNA clone was generated
in which the codon for the cysteine at position 24 was
changed into a codon for proline. The mutant construct
pABV911 as well as the parental LV clone pABV437 were
used to transcribe viral RNAs in vitro, which were sub-
sequently transfected into BHK-21 cells. Porcine alveolar
macrophages (PAMs) were then infected with the virus
present in the culture supernatants of the transfected cells,
the supernatants of the macrophages were harvested 24 h
p.i. and the virus titres of the resulting viruses vABV437
and vABV911 were determined by end-point titration. Sub-
sequently, a neutralization assay was performed in which
100 TCID50 of the two viruses were mixed with serial
dilutions of hybridoma culture supernatant of neutralizing
mAb P10/a46. The results showed that P10/a46 was able
to neutralize vABV911 completely up to a dilution of
1 : 1280, whereas the infection of parental LV clone was
not inhibited.
In conclusion, a proline residue at position 24 enables
recognition of a neutralization epitope that is located in
the N-terminal ectodomain.
DISCUSSION
In the present study, a neutralization epitope was identi-
fied in the GP5 protein of one of the European strains of
PRRSV. Using site-directed mutagenesis, we identified the
residue at position 24 as being essential for recognition by
the neutralizing mAbs. The epitope recognized in Pepscan
analysis stretched from residues 29 to 35. Furthermore, the
three neutralizing mAbs, P10/a46, P10/b38 and P4/a2-19,
each recognized the same epitope, as was previously
suggested by the results of Weiland et al. (1999).
Remarkably, the reactivity of the three neutralizing mAbs
in the Pepscan system was independent of the presence
(A) (B)
Fig. 4. Pepscan analyses of PRRSV GP5 proteins. Overlapping 12-mer peptides derived from the GP5 sequences of PRRSV
LV and of the PPV strain were tested for reactivity with anti-GP5 mAbs P10/a46, P10/b38 and P4/a2-19 (Slootstra et al.,
1997). (A) Overlapping 12-mer peptides derived from the GP5 sequence of the PPV strain. (B) Overlapping 12-mer peptides
derived from the GP5 sequence of PRRSV LV. Optical densities (OD) were determined with a ccd-camera. The values are
logarithmic values in a range of 0 to 4000. The Pepscan epitope is underlined, while the core sequence is printed in bold
letters.
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of a proline at position 24, since the set of 12-mers con-
taining a Cys24 and the 12-mers containing a Pro24 gave
comparable OD values in the Pepscan analysis. Moreover,
residue 24 is located within the signal peptide predicted
by the SignalP computer algorithm (Nielsen et al., 1997).
Several authors have reported that signal peptide cleavage
is predicted to occur between aa 32 and 33 (Meulenberg
et al., 1995; Rodriguez et al., 2001), i.e. in the core of the
epitope. In view of our results, however, it is more likely
either that the signal peptide is not cleaved off and the amino
acid residue at position 24 is itself part of the epitope in
the native protein, or that signal peptide cleavage occurs
more N-terminally.
Examples of non-cleaved predicted signal peptides exist
(Gewurz et al., 2002). Assuming that the signal peptide of
PRRSV GP5 is not cleaved, both residue 24 and the part
of the epitope recognized by the Pepscan analysis would
be present in the GP5 protein. A proline at position 24, a
helix-breaking residue, might be responsible for exposing
the epitope, whereas a cysteine at position 24 might hide
the epitope, possibly by forming a disulphide bond with
another cysteine residue in the GP5 protein.
However, sequence data from one of the escape mutant
viruses showed that the GP5 protein of this virus possessed
a leucine at position 24, emphasizing the importance of
the proline (E. Weiland, unpublished data). Therefore, a
more likely explanation might be that the signal peptide
might be cleaved but that Pro24 affects the site of this signal
peptide cleavage. Nothwehr & Gordon (1989) introduced
proline residues at various positions in the signal peptide
of human pre(Dpro)apolipoprotein A-II and observed that
the site of cleavage was affected by the location of a proline,
i.e. there was a tendency to maintain a distance of four to
five residues between the proline and the site of cleavage.
Furthermore, they reported that two or more potential
cleavage sites might compete for recognition by the signal
peptidase, although one site is preferred. Using the SignalP
computer algorithm for both the Cys24 and the Pro24 GP5
proteins, probable cleavage sites are located between
residues 28 and 29, 30 and 31, and 32 and 33 (Fig. 1B). In
the Cys24 protein, the preferred cleavage site is located
between residues 32 and 33. In the Pro24 protein, however,
the proline promotes the signal peptidase to cleave between
residues 28 and 29. This would result in a mature glyco-
protein that was two to three amino acids larger and thus
the presence of the epitope in the Pro24 protein, in contrast
to the Cys24 protein. Obviously, N-terminal sequencing of
bothmature glycoproteins should give the definitive answer.
Our data indicated that the identified neutralization epi-
tope is located at the N terminus of the GP5 ectodomain,
comprising residues 29–35 (Fig. 1B). The presence of both
linear and conformation-dependent neutralization epitopes
in the GP5 protein of PRRSV has been described by others,
although their locations in the protein have not been
determined (reviewed by Dea et al., 2000). Recently, both a
non-neutralization and a neutralization epitope located at
the N terminus of the GP5 of North American PRRSV
strains were identified by Ostrowski et al. (2002), com-
prising residues 27–31 and residues 37–45, respectively. The
neutralization epitope is located in an area that is con-
served among PRRSV isolates (Fig. 1B) and between PRRSV
and LDV. The VP-3P protein of LDV also contains a
neutralization epitope in its ectodomain that is mapped
between residues 37 and 60 (Li et al., 1998). Interestingly,
this epitope comprises the residues that form the main
recognition site in the epitope described by Ostrowski et al.
(2002). The ectodomain of the EAV ORF5 protein, GL, is
much longer and shows far less homology with the LDV and
PRRSV GP5 ectodomains. Nevertheless, it also contains
three overlapping neutralization epitopes, just upstream
of the first transmembrane segment (Balasuriya et al., 1995;
Chirnside et al., 1995; Glaser et al., 1995). The presence of
neutralizing epitopes in the GP5 ectodomains of PRRSV,
LDV and EAV leads to the suggestion that the GP5 ecto-
domains play an important role in arterivirus infection.
Another argument that pleads for such a role of the GP5
ectodomain is the fact that the disulphide bonds between
the LDV GP5 and M protein are essential for LDV infecti-
vity, suggesting that the heterodimeric GP5–M complexes
might be involved in receptor binding (Faaberg et al.,
1995). In addition, N-glycans associated with the ecto-
domain of the LDV GP5 protein determine LDV neuro-
pathogenicity and sensitivity to antibody neutralization
(Chen et al., 2000).
However, the strongest argument against such a role for
GP5 is that the exchange of the putative ectodomain of
the EAV equivalent of GP5 with that of PRRSV GP5 does
not alter its tropism (Dobbe et al., 2001). Moreover, recent
research in which the ectodomain of the M protein of
PRRSV was replaced by that of other arteriviruses revealed
that the tropism of the resulting chimeric viruses had
remained unchanged (Verheije et al., 2002). These authors
concluded that the heterodimeric GP5–M complexes are
essential for arterivirus assembly, but that they do not
determine host-cell specificity.
To explain these contradictory results, the role of GP5 in
PRRSV infection of PAMs should be further investigated.
Recently, Delputte et al. (2002) reported that PRRSV binds
to glycosaminoglycans at the cell surface of PAMs and that
this binding is probably mediated by the heterodimeric
GP5–M complexes. These complexes might thus initiate
PRRSV infection of PAMs by attachment to a low-affinity
receptor, followed by interaction of other PRRSV glyco-
protein(s) with a high-affinity receptor that determines
tropism. Our data suggest that neutralizing antibodies that
recognize the ectodomain of GP5 may interfere with this
initial step of the PRRSV infection. It is unlikely that the
neutralization epitope identified in this study plays an
important role in PRRSV infection, because the sequence
is variable (Stadejek et al., 2002) and it is easily lost from
the population (Weiland et al., 1999). The neighbouring
highly conserved region, however, containing the neutra-
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lization epitope identified by Ostrowski et al. (2002) and
implicated in heterodimerization with the M protein
(Verheije et al., 2002), might play a role in PRRSV infection.
Further studies will be necessary to clarify the role of GP5
in PRRSV infection in more detail.
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